West Pharmaceutical Services (WST) Expected to Post Quarterly Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is expected to be announcing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect West Pharmaceutical Services to post earnings of $2.20 per share and revenue of $827.12 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

West Pharmaceutical Services Stock Up 0.9%

WST stock opened at $398.29 on Wednesday. The business’s fifty day moving average is $364.15 and its 200-day moving average is $311.15. The company has a market cap of $28.03 billion, a P/E ratio of 51.00 and a beta of 1.13. West Pharmaceutical Services has a twelve month low of $223.83 and a twelve month high of $398.67.

West Pharmaceutical Services Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 18th. Investors of record on Wednesday, November 11th will be paid a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.3%. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Tuesday, November 10th. West Pharmaceutical Services’s payout ratio is presently 13.32%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on WST. KeyCorp upped their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Evercore reissued an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Citigroup raised their target price on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 7th. Finally, BNP Paribas Exane assumed coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 target price for the company. Twelve research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $391.17.

Insider Buying and Selling

In other news, VP Annette Favorite sold 2,524 shares of West Pharmaceutical Services stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total transaction of $921,260.00. Following the transaction, the vice president directly owned 21,818 shares of the company’s stock, valued at $7,963,570. This trade represents a 10.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 15,659 shares of company stock valued at $5,443,749 over the last ninety days. 0.60% of the stock is currently owned by corporate insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.